Biomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseases

World Allergy Organization Journal

Volumn 9, Issue 1, 2016, Pages

  Metcalfe, Dean D ^a   Pawankar, Ruby ^b   Ackerman, Steven J ^c   Akin, Cem ^d   Clayton, Frederic ^e   Falcone, Franco H ^f   Gleich, Gerald J ^e   Irani, Anne Marie ^g   Johansson, Mats W ^h   Klion, Amy D ^a   Leiferman, Kristin M ⁱ   Levi Schaffer, Francesca ^j   Nilsson, Gunnar ^k   Okayama, Yoshimichi ^l   Prussin, Calman ^a   Schroeder, John T ^m   Schwartz, Lawrence B ^g   Simon, Hans Uwe ⁿ   Walls, Andrew F ^o   Triggiani, Massimo ^p  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NIPPON MEDICAL SCHOOL   (Japan)

^c UNIVERSITY OF ILLINOIS   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^g VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^h UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

ⁱ UNIVERSITY OF UTAH   (United States)

^j HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^k KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^l NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^m JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁿ UNIVERSITY OF BERN   (Switzerland)

^o SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^p UNIVERSITY OF SALERNO   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BASOGRANULIN; BIOLOGICAL MARKER; CARBOXYPEPTIDASE; CARBOXYPEPTIDASE A3; CD203C ANTIGEN; CD63 ANTIGEN; CELL PROTEIN; CHARCOT LEYDEN CRYSTAL PROTEIN; CHYMASE; EOSINOPHIL CATIONIC PROTEIN; EOSINOPHIL PEROXIDASE; EOSINOPHIL PROTEIN X; FC EPSILON RECEPTOR 1; FC RECEPTOR; HEPARIN; HISTAMINE; INTERLEUKIN 2 RECEPTOR ALPHA; LYMPHOCYTE ANTIGEN; MAJOR BASIC PROTEIN; MONOCLONAL ANTIBODY; PEPTIDOLEUKOTRIENE; PROSTAGLANDIN D2; TRYPTASE; UNCLASSIFIED DRUG;

ALLERGIC DISEASE; ASTHMA; BASOPHIL; CELL ACTIVATION; DISEASE ASSOCIATION; DISEASE MARKER; EOSINOPHIL; HUMAN; IMMUNE RESPONSE; MAST CELL; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN FUNCTION; REVIEW;

EID: 85027929499     PISSN: None     EISSN: 19394551     Source Type: Journal    
DOI: 10.1186/s40413-016-0094-3     Document Type: Review

References (134)

1. Johansson MW. Activation states of blood eosinophils in asthma. Clin Exp Allergy. 2014;44(4):482-98.doi:10.1111/cea.12292.
2. Johansson MW, Mosher DF. Integrin activation states and eosinophil recruitment in asthma. Front Pharmacol. 2013;4:33.doi:10.3389/fphar.2013. 00033.
3. Rosenberg HF, Dyer KD, Foster PS. Eosinophils: changing perspectives in health and disease. Nat Rev Immunol. 2013;13(1):9-22.doi:10.1038/nri3341.
4. Driss V, Legrand F, Capron M. Eosinophils receptor profile. In: Lee J, Rosenberg HF, editors. Eosinophils in health and disease. 1st ed. Waltham: Elsevier/Academic Press; 2013. p. 30-8.
5. Johnsson M, Bove M, Bergquist H, Olsson M, Fornwall S, Hassel K, et al. Distinctive blood eosinophilic phenotypes and cytokine patterns in eosinophilic esophagitis, inflammatory bowel disease and airway allergy. J Innate Immun. 2011;3(6):594-604.doi:10.1159/000331326.
6. Lingblom C, Bergquist H, Johnsson M, Sundstrom P, Quiding-Jarbrink M, Bove M, et al. Topical corticosteroids do not revert the activated phenotype of eosinophils in eosinophilic esophagitis but decrease surface levels of CD18 resulting in diminished adherence to ICAM-1, ICAM-2, and endothelial cells. Inflammation. 2014;37(6):1932-44.doi:10.1007/s10753-014-9926-x.
7. Simon HU, Plotz S, Simon D, Seitzer U, Braathen LR, Menz G, et al. Interleukin-2 primes eosinophil degranulation in hypereosinophilia and Wells' syndrome. Eur J Immunol. 2003;33(4):834-9.doi:10.1002/eji. 200323727.
8. Straumann A, Kristl J, Conus S, Vassina E, Spichtin HP, Beglinger C, et al. Cytokine expression in healthy and inflamed mucosa: probing the role of eosinophils in the digestive tract. Inflamm Bowel Dis. 2005;11(8):720-6.
9. Hansel TT, Braunstein JB, Walker C, Blaser K, Bruijnzeel PL, Virchow Jr JC, et al. Sputum eosinophils from asthmatics express ICAM-1 and HLA-DR. Clin Exp Immunol. 1991;86(2):271-7.
10. Toma T, Mizuno K, Okamoto H, Kanegane C, Ohta K, Ikawa Y, et al. Expansion of activated eosinophils in infants with severe atopic dermatitis. Pediatr Int. 2005;47(1):32-8.doi:10.1111/j.1442-200x.2004.02004.x.
11. Stein ML, Collins MH, Villanueva JM, Kushner JP, Putnam PE, Buckmeier BK, et al. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol. 2006;118(6):1312-9.doi:10.1016/j.jaci.2006.09.007.
12. Kita H, Adolphoson CR, Gleich GJ. Biology of eosinophils. In: Adkinson NF, Yunginger JW, Busse WW, Bochner BS, Holgate ST, Simons FER, editors. Middleton's allergy: principles & practice. 6th ed. St. Louis: Mosby; 2003. p. 305-32.
13. Gleich GJ, Loegering DA, Mann KG, Maldonado JE. Comparative properties of the Charcot-Leyden crystal protein and the major basic protein from human eosinophils. J Clin Invest. 1976;57(3):633-40.doi:10.1172/JCI108319.
14. Barker RL, Gleich GJ, Pease LR. Acidic precursor revealed in human eosinophil granule major basic protein cDNA. J Exp Med. 1988;168(4):1493-8.
15. Plager DA, Loegering DA, Weiler DA, Checkel JL, Wagner JM, Clarke NJ, et al. A novel and highly divergent homolog of human eosinophil granule major basic protein. J Biol Chem. 1999;274(20):14464-73.
16. Soragni A, Yousefi S, Stoeckle C, Soriaga AB, Sawaya MR, Kozlowski E, et al. Toxicity of eosinophil MBP is repressed by intracellular crystallization and promoted by extracellular aggregation. Mol Cell. 2015;57(6):1011-21.doi:10. 1016/j.molcel.2015.01.026.
17. Woschnagg C, Rubin J, Venge P. Eosinophil cationic protein (ECP) is processed during secretion. J Immunol. 2009;183(6):3949-54.doi:10.4049/jimmunol.0900509.
18. Koh GC, Shek LP, Goh DY, Van Bever H, Koh DS. Eosinophil cationic protein: is it useful in asthma? A systematic review. Respir Med. 2007;101(4):696-705.doi:10.1016/j.rmed.2006.08.012.
19. Lowhagen O, Wever AM, Lusuardi M, Moscato G, De Backer WA, Gandola L, et al. The inflammatory marker serum eosinophil cationic protein (ECP) compared with PEF as a tool to decide inhaled corticosteroid dose in asthmatic patients. Respir Med. 2002;96(2):95-101.
20. Bjork A, Venge P, Peterson CG. Measurements of ECP in serum and the impact of plasma coagulation. Allergy. 2000;55(5):442-8.
21. Plotz SG, Simon HU, Darsow U, Simon D, Vassina E, Yousefi S, et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med. 2003;349(24):2334-9.doi:10.1056/NEJMoa031261.
22. Sur S, Glitz DG, Kita H, Kujawa SM, Peterson EA, Weiler DA, et al. Localization of eosinophil-derived neurotoxin and eosinophil cationic protein in neutrophilic leukocytes. J Leukoc Biol. 1998;63(6):715-22.
23. Wang JG, Mahmud SA, Thompson JA, Geng JG, Key NS, Slungaard A. The principal eosinophil peroxidase product, HOSCN, is a uniquely potent phagocyte oxidant inducer of endothelial cell tissue factor activity: a potential mechanism for thrombosis in eosinophilic inflammatory states. Blood. 2006; 107(2):558-65.doi:10.1182/blood-2005-05-2152.
24. Henderson WR, Jorg A, Klebanoff SJ. Eosinophil peroxidase-mediated inactivation of leukotrienes B4, C4, and D4. J Immunol. 1982;128(6):2609-13.
25. Ulrich M, Petre A, Youhnovski N, Promm F, Schirle M, Schumm M, et al. Post-translational tyrosine nitration of eosinophil granule toxins mediated by eosinophil peroxidase. J Biol Chem. 2008;283(42):28629-40.doi:10.1074/jbc.M801196200.
26. Ackerman SJ, Corrette SE, Rosenberg HF, Bennett JC, Mastrianni DM, Nicholson-Weller A, et al. Molecular cloning and characterization of human eosinophil Charcot-Leyden crystal protein (lysophospholipase). Similarities to IgE binding proteins and the S-type animal lectin superfamily. J Immunol. 1993;150(2):456-68.
27. Weller PF, Bach DS, Austen KF. Biochemical characterization of human eosinophil Charcot-Leyden crystal protein (lysophospholipase). J Biol Chem. 1984;259(24):15100-5.
28. Leonidas DD, Elbert BL, Zhou Z, Leffler H, Ackerman SJ, Acharya KR. Crystal structure of human Charcot-Leyden crystal protein, an eosinophil lysophospholipase, identifies it as a new member of the carbohydrate-binding family of galectins. Structure. 1995;3(12):1379-93.
29. Ackerman SJ, Weil GJ, Gleich GJ. Formation of Charcot-Leyden crystals by human basophils. J Exp Med. 1982;155(6):1597-609.
30. Ackerman SJ, Liu L, Kwatia MA, Savage MP, Leonidas DD, Swaminathan GJ, et al. Charcot-Leyden crystal protein (galectin-10) is not a dual function galectin with lysophospholipase activity but binds a lysophospholipase inhibitor in a novel structural fashion. J Biol Chem. 2002;277(17):14859-68.doi:10.1074/jbc.M200221200.
31. Kubach J, Lutter P, Bopp T, Stoll S, Becker C, Huter E, et al. Human CD4 + CD25+ regulatory T cells: proteome analysis identifies galectin-10 as a novel marker essential for their anergy and suppressive function. Blood. 2007; 110(5):1550-8.doi:10.1182/blood-2007-01-069229.
32. Acharya KR, Ackerman SJ. Eosinophil granule proteins: form and function. J Biol Chem. 2014;289(25):17406-15.doi:10.1074/jbc.R113.546218.
33. Furuta GT, Kagalwalla AF, Lee JJ, Alumkal P, Maybruck BT, Fillon S, et al. The oesophageal string test: a novel, minimally invasive method measures mucosal inflammation in eosinophilic oesophagitis. Gut. 2013; 62(10):1395-405.doi:10.1136/gutjnl-2012-303171.
34. Chua JC, Douglass JA, Gillman A, O'Hehir RE, Meeusen EN. Galectin-10, a potential biomarker of eosinophilic airway inflammation. PLoS One. 2012; 7(8):e42549.doi:10.1371/journal.pone.0042549.
35. De Re V, Simula MP, Cannizzaro R, Pavan A, De Zorzi MA, Toffoli G, et al. Galectin-10, eosinophils, and celiac disease. Ann N Y Acad Sci. 2009;1173: 357-64.doi:10.1111/j.1749-6632.2009.04627.x.
36. Bryborn M, Hallden C, Sall T, Cardell LO. CLC-a novel susceptibility gene for allergic rhinitis? Allergy. 2010;65(2):220-8.doi:10.1111/j.1398-9995.2009. 02141.x.
37. Abu-Ghazaleh RI, Dunnette SL, Loegering DA, Checkel JL, Kita H, Thomas LL, et al. Eosinophil granule proteins in peripheral blood granulocytes. J Leukoc Biol. 1992;52(6):611-8.
38. Durack DT, Ackerman SJ, Loegering DA, Gleich GJ. Purification of human eosinophil-derived neurotoxin. Proc Natl Acad Sci U S A. 1981;78(8):5165-9.
39. Domachowske JB, Dyer KD, Bonville CA, Rosenberg HF. Recombinant human eosinophil-derived neurotoxin/RNase 2 functions as an effective antiviral agent against respiratory syncytial virus. J Infect Dis. 1998;177(6): 1458-64.
40. Sorrentino S, Glitz DG, Hamann KJ, Loegering DA, Checkel JL, Gleich GJ. Eosinophil-derived neurotoxin and human liver ribonuclease. Identity of structure and linkage of neurotoxicity to nuclease activity. J Biol Chem. 1992;267(21):14859-65.
41. Yang D, Chen Q, Rosenberg HF, Rybak SM, Newton DL, Wang ZY, et al. Human ribonuclease A superfamily members, eosinophil-derived neurotoxin and pancreatic ribonuclease, induce dendritic cell maturation and activation. J Immunol. 2004;173(10):6134-42.
42. Yang D, Chen Q, Su SB, Zhang P, Kurosaka K, Caspi RR, et al. Eosinophilderived neurotoxin acts as an alarmin to activate the TLR2-MyD88 signal pathway in dendritic cells and enhances Th2 immune responses. J Exp Med. 2008;205(1):79-90.doi:10.1084/jem.20062027.
43. Ackerman SJ, Kephart GM, Francis H, Awadzi K, Gleich GJ, Ottesen EA. Eosinophil degranulation. An immunologic determinant in the pathogenesis of the Mazzotti reaction in human onchocerciasis. J Immunol. 1990;144(10): 3961-9.
44. Konikoff MR, Blanchard C, Kirby C, Buckmeier BK, Cohen MB, Heubi JE, et al. Potential of blood eosinophils, eosinophil-derived neurotoxin, and eotaxin-3 as biomarkers of eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2006; 4(11):1328-36.doi:10.1016/j.cgh.2006.08.013.
45. Subbarao G, Rosenman MB, Ohnuki L, Georgelas A, Davis M, Fitzgerald JF, et al. Exploring potential noninvasive biomarkers in eosinophilic esophagitis in children. J Pediatr Gastroenterol Nutr. 2011;53(6):651-8.doi:10.1097/MPG. 0b013e318228cee6.
46. Kim CK, Seo JK, Ban SH, Fujisawa T, Kim DW, Callaway Z. Eosinophil-derived neurotoxin levels at 3 months post-respiratory syncytial virus bronchiolitis are a predictive biomarker of recurrent wheezing. Biomarkers. 2013;18(3): 230-5.doi:10.3109/1354750X.2013.773078.
47. Schulman ES, Kagey-Sobotka A, MacGlashan Jr DW, Adkinson Jr NF, Peters SP, Schleimer RP, et al. Heterogeneity of human mast cells. J Immunol. 1983;131(4):1936-41.
48. Casale TB, Wood D, Richerson HB, Trapp S, Metzger WJ, Zavala D, et al. Elevated bronchoalveolar lavage fluid histamine levels in allergic asthmatics are associated with methacholine bronchial hyperresponsiveness. J Clin Invest. 1987;79(4):1197-203.doi:10.1172/JCI112937.
49. Kaplan AP, Horakova Z, Katz SI. Assessment of tissue fluid histamine levels in patients with urticaria. J Allergy Clin Immunol. 1978;61(6):350-4.
50. Pollock I, Murdoch RD, Lessof MH. Plasma histamine and clinical tolerance to infused histamine in normal, atopic and urticarial subjects. Agents Actions. 1991;32(3-4):359-65.
51. Granerus G, Lonnqvist B, Wass U. Determination of the histamine metabolite tele-methylimidazoleacetic acid and of creatinine in urine by the same HPLC system. Inflamm Res. 1999;48(2):75-80.
52. Keyzer JJ, de Monchy JG, van Doormaal JJ, van Voorst Vader PC. Improved diagnosis of mastocytosis by measurement of urinary histamine metabolites. N Engl J Med. 1983;309(26):1603-5.doi:10.1056/NEJM198312293092603.
53. Kolmert J, Forngren B, Lindberg J, Ohd J, Aberg KM, Nilsson G, et al. A quantitative LC/MS method targeting urinary 1-methyl-4-imidazoleacetic acid for safety monitoring of the global histamine turnover in clinical studies. Anal Bioanal Chem. 2014;406(6):1751-62.doi:10.1007/s00216-013-7594-6.
54. Metcalfe DD, Lewis RA, Silbert JE, Rosenberg RD, Wasserman SI, Austen KF. Isolation and characterization of heparin from human lung. J Clin Invest. 1979;64(6):1537-43.doi:10.1172/JCI109613.
55. Metcalfe DD, Soter NA, Wasserman SI, Austen KF. Identification of sulfated mucopolysaccharides including heparin in the lesional skin of a patient with mastocytosis. J Invest Dermatol. 1980;74(4):210-5.
56. Sucker C, Mansmann G, Steiner S, Gattermann N, Schmitt-Graeff A, Loncar R, et al. Fatal bleeding due to a heparin-like anticoagulant in a 37-year-old woman suffering from systemic mastocytosis. Clin Appl Thromb Hemost. 2008;14(3):360-4.doi:10.1177/1076029607309173.
57. Seidel H, Molderings GJ, Oldenburg J, Meis K, Kolck UW, Homann J, et al. Bleeding diathesis in patients with mast cell activation disease. Thromb Haemost. 2011;106(5):987-9.doi:10.1160/TH11-05-0351.
58. Oschatz C, Maas C, Lecher B, Jansen T, Bjorkqvist J, Tradler T, et al. Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity. 2011;34(2):258-68.doi:10.1016/j.immuni.2011.02.008.
59. Pallaoro M, Fejzo MS, Shayesteh L, Blount JL, Caughey GH. Characterization of genes encoding known and novel human mast cell tryptases on chromosome 16p13.3. J Biol Chem. 1999;274(6):3355-62.
60. Schwartz LB. Diagnostic value of tryptase in anaphylaxis and mastocytosis. Immunol Allergy Clin North Am. 2006;26(3):451-63.doi:10.1016/j.iac.2006.05.010.
61. Le QT, Gomez G, Zhao W, Hu J, Xia HZ, Fukuoka Y, et al. Processing of human protryptase in mast cells involves cathepsins L, B, and C. J Immunol. 2011;187(4):1912-8.doi:10.4049/jimmunol.1001806.
62. Le QT, Min HK, Xia HZ, Fukuoka Y, Katunuma N, Schwartz LB. Promiscuous processing of human alphabeta-protryptases by cathepsins L, B, and C. J Immunol. 2011;186(12):7136-43.doi:10.4049/jimmunol.1001804.
63. Sverrild A, van der Sluis S, Kyvik KO, Garvey LH, Porsbjerg C, Backer V, et al. Genetic factors account for most of the variation in serum tryptase-a twin study. Ann Allergy Asthma Immunol. 2013;111(4):286-9.doi:10.1016/j.anai. 2013.07.011.
64. Alvarez-Twose I, Zanotti R, Gonzalez-de-Olano D, Bonadonna P, Vega A, Matito A, et al. Nonaggressive systemic mastocytosis (SM) without skin lesions associated with insect-induced anaphylaxis shows unique features versus other indolent SM. J Allergy Clin Immunol. 2014;133(2):520-8.doi:10. 1016/j.jaci.2013.06.020.
65. Bonadonna P, Perbellini O, Passalacqua G, Caruso B, Colarossi S, Dal Fior D, et al. Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. J Allergy Clin Immunol. 2009;123(3):680-6.doi:10.1016/j.jaci.2008.11.018.
66. Valent P, Akin C, Arock M, Brockow K, Butterfield JH, Carter MC, et al. Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal. Int Arch Allergy Immunol. 2012;157(3):215-25.doi:10.1159/000328760.
67. Hsu FI, Boyce JA. Biology of mast cells and their mediators. In: Adkinson Jr NF, Busse WW, Bochner BS, Holgate ST, Simons FER, Lemanske Jr RF, editors. Middleton's allergy: principles & practice. 7th ed. Philadelphia: Mosby/Elsevier; 2009. p. 311-28.
68. He A, Shi GP. Mast cell chymase and tryptase as targets for cardiovascular and metabolic diseases. Curr Pharm Des. 2013;19(6):1114-25.
69. Oskeritzian CA. Mast cells and wound healing. Adv Wound Care (New Rochelle). 2012;1(1):23-8.doi:10.1089/wound.2011.0357.
70. Takato H, Yasui M, Ichikawa Y, Waseda Y, Inuzuka K, Nishizawa Y, et al. The specific chymase inhibitor TY-51469 suppresses the accumulation of neutrophils in the lung and reduces silica-induced pulmonary fibrosis in mice. Exp Lung Res. 2011;37(2):101-8.doi:10.3109/01902148.2010.520815.
71. Walter M, Sutton RM, Schechter NM. Highly efficient inhibition of human chymase by alpha(2)-macroglobulin. Arch Biochem Biophys. 1999;368(2): 276-84.doi:10.1006/abbi.1999.1309.
72. Raymond WW, Su S, Makarova A, Wilson TM, Carter MC, Metcalfe DD, et al. Alpha 2-macroglobulin capture allows detection of mast cell chymase in serum and creates a reservoir of angiotensin II-generating activity. J Immunol. 2009;182(9):5770-7.doi:10.4049/jimmunol.0900127.
73. Goldstein SM, Kaempfer CE, Kealey JT, Wintroub BU. Human mast cell carboxypeptidase. Purification and characterization. J Clin Invest. 1989;83(5): 1630-6.doi:10.1172/JCI114061.
74. Fajt ML, Wenzel SE. Mast cells, their subtypes, and relation to asthma phenotypes. Ann Am Thorac Soc. 2013;10(Suppl):S158-64.doi:10.1513/AnnalsATS.201303-064AW.
75. Takabayashi T, Kato A, Peters AT, Suh LA, Carter R, Norton J, et al. Glandular mast cells with distinct phenotype are highly elevated in chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2012;130(2):410-20.doi:10.1016/j.jaci.2012.02.046. e5.
76. D'Ambrosio C, Akin C, Wu Y, Magnusson MK, Metcalfe DD. Gene expression analysis in mastocytosis reveals a highly consistent profile with candidate molecular markers. J Allergy Clin Immunol. 2003;112(6):1162-70.doi:10. 1016/j.jaci.2003.07.008.
77. Pan Q, Ding MF, Zhang S, Ning Y, Liu HW, Wei H, et al. Measurement of plasma mast cell carboxypeptidase and chymase levels in children with allergic diseases. Zhongguo Dang Dai Er Ke Za Zhi. 2011;13(10):814-6.
78. Simons FE, Frew AJ, Ansotegui IJ, Bochner BS, Golden DB, Finkelman FD, et al. Risk assessment in anaphylaxis: current and future approaches. J Allergy Clin Immunol. 2007;120(1 Suppl):S2-24.doi:10.1016/j.jaci.2007.05.001.
79. Fanning LB, Boyce JA. Lipid mediators and allergic diseases. Ann Allergy Asthma Immunol. 2013;111(3):155-62.doi:10.1016/j.anai.2013.06.031.
80. Boyce JA. Eicosanoid mediators of mast cells: receptors, regulation of synthesis, and pathobiologic implications. Chem Immunol Allergy. 2005;87: 59-79.doi:10.1159/000087571.
81. Morrow JD, Guzzo C, Lazarus G, Oates JA, Roberts 2nd LJ. Improved diagnosis of mastocytosis by measurement of the major urinary metabolite of prostaglandin D2. J Invest Dermatol. 1995;104(6):937-40.
82. Ravi A, Butterfield J, Weiler CR. Mast cell activation syndrome: improved identification by combined determinations of serum tryptase and 24-hour urine 11beta-prostaglandin2alpha. J Allergy Clin Immunol Pract. 2014;2(6): 775-8.doi:10.1016/j.jaip.2014.06.011.
83. Murphy RC, Hammarstrom S, Samuelsson B. Leukotriene C: a slow-reacting substance from murine mastocytoma cells. Proc Natl Acad Sci U S A. 1979; 76(9):4275-9.
84. Kanaoka Y, Boyce JA. Cysteinyl leukotrienes and their receptors; emerging concepts. Allergy Asthma Immunol Res. 2014;6(4):288-95.doi:10.4168/aair. 2014.6.4.288.
85. Butterfield JH. Increased leukotriene E4 excretion in systemic mastocytosis. Prostaglandins Other Lipid Mediat. 2010;92(1-4):73-6.doi:10.1016/j. prostaglandins.2010.03.003.
86. Valent P, Cerny-Reiterer S, Herrmann H, Mirkina I, George TI, Sotlar K, et al. Phenotypic heterogeneity, novel diagnostic markers, and target expression profiles in normal and neoplastic human mast cells. Best Pract Res Clin Haematol. 2010;23(3):369-78.doi:10.1016/j.beha.2010.07. 003.
87. Pols MS, Klumperman J. Trafficking and function of the tetraspanin CD63. Exp Cell Res. 2009;315(9):1584-92.doi:10.1016/j.yexcr.2008.09.020.
88. He SH, Zhang HY, Zeng XN, Chen D, Yang PC. Mast cells and basophils are essential for allergies: mechanisms of allergic inflammation and a proposed procedure for diagnosis. Acta Pharmacol Sin. 2013;34(10):1270-83.doi:10. 1038/aps.2013.88.
89. Sturm EM, Kranzelbinder B, Heinemann A, Groselj-Strele A, Aberer W, Sturm GJ. CD203c-based basophil activation test in allergy diagnosis: characteristics and differences to CD63 upregulation. Cytometry B Clin Cytom. 2010;78(5):308-18.doi:10.1002/cyto.b.20526.
90. Kraft S, Fleming T, Billingsley JM, Lin SY, Jouvin MH, Storz P, et al. Anti-CD63 antibodies suppress IgE-dependent allergic reactions in vitro and in vivo. J Exp Med. 2005;201(3):385-96.doi:10.1084/jem.20042085.
91. Kraft S, Jouvin MH, Kulkarni N, Kissing S, Morgan ES, Dvorak AM, et al. The tetraspanin CD63 is required for efficient IgE-mediated mast cell degranulation and anaphylaxis. J Immunol. 2013;191(6):2871-8.doi:10.4049/jimmunol.1202323.
92. Buhring HJ, Streble A, Valent P. The basophil-specific ectoenzyme E-NPP3 (CD203c) as a marker for cell activation and allergy diagnosis. Int Arch Allergy Immunol. 2004;133(4):317-29.doi:10.1159/000077351.
93. Yano Y, Hayashi Y, Sano K, Shinmaru H, Kuroda Y, Yokozaki H, et al. Expression and localization of ecto-nucleotide pyrophosphatase/phosphodiesterase I-3 (ENPP3/CD203c/PD-I beta/B10/gp130RB13-6) in human colon carcinoma. Int J Mol Med. 2003;12(5):763-6.
94. Hauswirth AW, Escribano L, Prados A, Nunez R, Mirkina I, Kneidinger M, et al. CD203c is overexpressed on neoplastic mast cells in systemic mastocytosis and is upregulated upon IgE receptor cross-linking. Int J Immunopathol Pharmacol. 2008;21(4):797-806.
95. Ono E, Taniguchi M, Higashi N, Mita H, Kajiwara K, Yamaguchi H, et al. CD203c expression on human basophils is associated with asthma exacerbation. J Allergy Clin Immunol. 2010;125(2):483-9.doi:10.1016/j.jaci.2009.10.074. e3.
96. Perini GF, Pro B. Brentuximab Vedotin in CD30+ Lymphomas. Biol Ther. 2013;3:15-23.doi:10.1007/s13554-013-0008-7.
97. Morgado JM, Perbellini O, Johnson RC, Teodosio C, Matito A, Alvarez-Twose I, et al. CD30 expression by bone marrowmast cells from different diagnostic variants of systemic mastocytosis. Histopathology. 2013;63(6):780-7.doi:10.1111/his.12221.
98. Malek TR. The biology of interleukin-2. Annu Rev Immunol. 2008;26:453-79.doi:10.1146/annurev.immunol.26.021607.090357.
99. Schernthaner GH, Hauswirth AW, Baghestanian M, Agis H, Ghannadan M, Worda C, et al. Detection of differentiation-and activation-linked cell surface antigens on cultured mast cell progenitors. Allergy. 2005;60(10): 1248-55.doi:10.1111/j.1398-9995.2005.00865.x.
100. Pawankar R, Okuda M, Yssel H, Okumura K, Ra C. Nasal mast cells in perennial allergic rhinitics exhibit increased expression of the Fc epsilonRI, CD40L, IL-4, and IL-13, and can induce IgE synthesis in B cells. J Clin Invest. 1997;99(7):1492-9.doi:10.1172/JCI119311.
101. Kobayashi H, Okayama Y, Ishizuka T, Pawankar R, Ra C, Mori M. Production of IL-13 by human lung mast cells in response to Fcepsilon receptor crosslinkage. Clin Exp Allergy. 1998;28(10):1219-27.
102. Yamaguchi M, Lantz CS, Oettgen HC, Katona IM, Fleming T, Miyajima I, et al. IgE enhances mouse mast cell Fc(epsilon)RI expression in vitro and in vivo: evidence for a novel amplification mechanism in IgE-dependent reactions. J Exp Med. 1997;185(4):663-72.
103. Pawankar R, Ra C. IgE-Fc epsilonRI-mast cell axis in the allergic cycle. Clin Exp Allergy. 1998;28 Suppl 3:6-14.
104. Rajakulasingam K, Till S, Ying S, Humbert M, Barkans J, Sullivan M, et al. Increased expression of high affinity IgE (FcepsilonRI) receptor-alpha chain mRNA and protein-bearing eosinophils in human allergen-induced atopic asthma. Am J Respir Crit Care Med. 1998;158(1):233-40.doi:10.1164/ajrccm. 158.1.9708106.
105. Humbert M, Grant JA, Taborda-Barata L, Durham SR, Pfister R, Menz G, et al. High-affinity IgE receptor (FcepsilonRI)-bearing cells in bronchial biopsies from atopic and nonatopic asthma. Am J Respir Crit Care Med. 1996;153(6 Pt 1):1931-7.doi:10.1164/ajrccm.153.6.8665058.
106. Andersson CK, Tufvesson E, Aronsson D, Bergqvist A, Mori M, Bjermer L, et al. Alveolar mast cells shift to an FcepsilonRI-expressing phenotype in mild atopic asthma: a novel feature in allergic asthma pathology. Allergy. 2011;66(12):1590-7.doi:10.1111/j.1398-9995.2011.02723.x.
107. Andersson CK, Mori M, Bjermer L, Lofdahl CG, Erjefalt JS. Novel site-specific mast cell subpopulations in the human lung. Thorax. 2009;64(4):297-305.doi:10.1136/thx.2008.101683.
108. Bergqvist A, Andersson CK, Mori M, Walls AF, Bjermer L, Erjefalt JS. Alveolar T-helper type-2 immunity in atopic asthma is associated with poor clinical control. Clin Sci (Lond). 2015;128(1):47-56.doi:10.1042/CS20140309.
109. Kiyokawa H, Matsumoto H, Nakaji H, Niimi A, Ito I, Ono K, et al. Centrilobular opacities in the asthmatic lung successfully treated with inhaled ciclesonide and tiotropium: with assessment of alveolar nitric oxide levels. Allergol Int. 2011;60(3):381-5.doi:10.2332/allergolint.10-CR-0251.
110. Arock M, Schneider E, Boissan M, Tricottet V, Dy M. Differentiation of human basophils: an overview of recent advances and pending questions. J Leukoc Biol. 2002;71(4):557-64.
111. Naclerio RM, Baroody FM, Kagey-Sobotka A, Lichtenstein LM. Basophils and eosinophils in allergic rhinitis. J Allergy Clin Immunol. 1994;94(6 Pt 2):1303-9.
112. Uyttebroek AP, Sabato V, Faber MA, Cop N, Bridts CH, Lapeere H, et al. Basophil activation tests: time for a reconsideration. Expert Rev Clin Immunol. 2014;10(10):1325-35.doi:10.1586/1744666X.2014.959498.
113. Ebo DG, Bridts CH, Mertens CH, Hagendorens MM, Stevens WJ, De Clerck LS. Analyzing histamine release by flow cytometry (HistaFlow): a novel instrument to study the degranulation patterns of basophils. J Immunol Methods. 2012;375(1-2):30-8.doi:10.1016/j.jim.2011.09.003.
114. Shamji MH, Layhadi JA, Scadding GW, Cheung DK, Calderon MA, Turka LA, et al. Basophil expression of diamine oxidase: a novel biomarker of allergen immunotherapy response. J Allergy Clin Immunol. 2015;135(4):913-21.doi: 10.1016/j.jaci.2014.09.049. e9.
115. Schleimer RP, Davidson DA, Peters SP, Lichtenstein LM. Inhibition of human basophil leukotriene release by antiinflammatory steroids. Int Arch Allergy Appl Immunol. 1985;77(1-2):241-3.
116. Schroeder JT. Basophils: emerging roles in the pathogenesis of allergic disease. Immunol Rev. 2011;242(1):144-60.doi:10.1111/j.1600-065X.2011. 01023.x.
117. Austen KF, Maekawa A, Kanaoka Y, Boyce JA. The leukotriene E4 puzzle: finding the missing pieces and revealing the pathobiologic implications. J Allergy Clin Immunol. 2009;124(3):406-14.doi:10.1016/j.jaci.2009.05.046. quiz 15-6.
118. Schroeder JT, Kagey-Sobotka A. Assay methods for measurement of mediators and markers of allergic inflammation. In: Rose NR, Hamilton RG, Detrick B, editors. Manual of clinical laboratory immunology. 6th ed. Washington: ASM Press; 2002. p. 899-909.
119. Karasuyama H, Yamanishi Y. Basophils have emerged as a key player in immunity. Curr Opin Immunol. 2014;31:1-7.doi:10.1016/j.coi.2014.07.004.
120. Plager DA, Weiss EA, Kephart GM, Mocharla RM, Matsumoto R, Checkel JL, et al. Identification of basophils by a mAb directed against pro-major basic protein 1. J Allergy Clin Immunol. 2006;117(3):626-34.doi:10.1016/j.jaci.2005. 10.023.
121. Kepley CL, McFeeley PJ, Oliver JM, Lipscomb MF. Immunohistochemical detection of human basophils in postmortem cases of fatal asthma. Am J Respir Crit Care Med. 2001;164(6):1053-8.doi:10.1164/ajrccm.164.6.2102025.
122. Foster B, Schwartz LB, Devouassoux G, Metcalfe DD, Prussin C. Characterization of mast-cell tryptase-expressing peripheral blood cells as basophils. J Allergy Clin Immunol. 2002;109(2):287-93.
123. Cromheecke JL, Nguyen KT, Huston DP. Emerging role of human basophil biology in health and disease. Curr Allergy Asthma Rep. 2014;14(1):408.doi: 10.1007/s11882-013-0408-2.
124. Sturm GJ, Kranzelbinder B, Sturm EM, Heinemann A, Groselj-Strele A, Aberer W. The basophil activation test in the diagnosis of allergy: technical issues and critical factors. Allergy. 2009;64(9):1319-26.doi:10.1111/j.1398-9995.2009. 02004.x.
125. McGowan EC, Saini S. Update on the performance and application of basophil activation tests. Curr Allergy Asthma Rep. 2013;13(1):101-9.doi:10. 1007/s11882-012-0324-x.
126. Boumiza R, Debard AL, Monneret G. The basophil activation test by flow cytometry: recent developments in clinical studies, standardization and emerging perspectives. Clin Mol Allergy. 2005;3:9.doi:10.1186/1476-7961-3-9.
127. Hauswirth AW, Sonneck K, Florian S, Krauth MT, Bohm A, Sperr WR, et al. Interleukin-3 promotes the expression of E-NPP3/CD203C on human blood basophils in healthy subjects and in patients with birch pollen allergy. Int J Immunopathol Pharmacol. 2007;20(2):267-78.
128. Hennersdorf F, Florian S, Jakob A, Baumgartner K, Sonneck K, Nordheim A, et al. Identification of CD13, CD107a, and CD164 as novel basophilactivation markers and dissection of two response patterns in time kinetics of IgE-dependent upregulation. Cell Res. 2005;15(5):325-35.doi:10.1038/sj.cr. 7290301.
129. MacGlashan Jr D. Expression of CD203c and CD63 in human basophils: relationship to differential regulation of piecemeal and anaphylactic degranulation processes. Clin Exp Allergy. 2010;40(9):1365-77.doi:10.1111/j. 1365-2222.2010.03572.x.
130. McEuen AR, Calafat J, Compton SJ, Easom NJ, Buckley MG, Knol EF, et al. Mass, charge, and subcellular localization of a unique secretory product identified by the basophil-specific antibody BB1. J Allergy Clin Immunol. 2001;107(5):842-8.doi:10.1067/mai.2001.114650.
131. Mochizuki A, McEuen AR, Buckley MG, Walls AF. The release of basogranulin in response to IgE-dependent and IgE-independent stimuli: validity of basogranulin measurement as an indicator of basophil activation. J Allergy Clin Immunol. 2003;112(1):102-8.
132. Agis H, Krauth MT, Bohm A, Mosberger I, Mullauer L, Simonitsch-Klupp I, et al. Identification of basogranulin (BB1) as a novel immunohistochemical marker of basophils in normal bone marrow and patients with myeloproliferative disorders. Am J Clin Pathol. 2006;125(2):273-81.doi:10. 1309/M9FQ-MQGF-6616-7N2X.
133. Nguyen T, Gernez Y, Fuentebella J, Patel A, Tirouvanziam R, Reshamwala N, et al. Immunophenotyping of peripheral eosinophils demonstrates activation in eosinophilic esophagitis. J Pediatr Gastroenterol Nutr. 2011; 53(1):40-7.doi:10.1097/MPG.0b013e318212647a.
134. Heinisch IV, Bizer C, Volgger W, Simon HU. Functional CD137 receptors are expressed by eosinophils from patients with IgE-mediated allergic responses but not by eosinophils from patients with non-IgE-mediated eosinophilic disorders. J Allergy Clin Immunol. 2001;108(1):21-8.doi:10.1067/mai.2001.116864.